Successful management of splenomegaly with ruxolitinib prior to allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia transformed from post-polycythemia vera myelofibrosis

  • FUJISHIMA Masumi
    Department of Hematology, Nephrology, and Rheumatology, Akita University Hospital
  • FUJISHIMA Naohito
    Department of Hematology, Nephrology, and Rheumatology, Akita University Hospital Division of Blood Transfusion, Akita University Hospital
  • KITADATE Akihiro
    Department of Hematology, Nephrology, and Rheumatology, Akita University Hospital
  • GUO Yongmei
    Department of Hematology, Nephrology, and Rheumatology, Akita University Hospital
  • WATANABE Atsushi
    Department of Hematology, Nephrology, and Rheumatology, Akita University Hospital
  • UBUKAWA Kumi
    Department of Hematology, Nephrology, and Rheumatology, Akita University Hospital
  • NARA Miho
    Department of Hematology, Nephrology, and Rheumatology, Akita University Hospital
  • YOSHIOKA Tomoko
    Department of Hematology, Nephrology, and Rheumatology, Akita University Hospital
  • KAMEOKA Yoshihiro
    Department of Hematology, Nephrology, and Rheumatology, Akita University Hospital
  • TAKAHASHI Naoto
    Department of Hematology, Nephrology, and Rheumatology, Akita University Hospital

Bibliographic Information

Other Title
  • 同種造血幹細胞移植前にruxolitinibで脾腫のコントロールを行った多血症線維化期から移行した急性骨髄性白血病
  • 症例報告 第122回日本血液学会東北地方会 会長推薦演題 同種造血幹細胞移植前にruxolitinibで脾腫のコントロールを行った多血症線維化期から移行した急性骨髄性白血病
  • ショウレイ ホウコク ダイ122カイ ニホン ケツエキ ガッカイ トウホク チホウカイ カイチョウ スイセン エンダイ ドウシュ ゾウケツ カンサイボウ イショク マエ ニ ruxolitinib デ ヒシュ ノ コントロール オ オコナッタ タケッショウ センイカキ カラ イコウ シタ キュウセイ コツズイセイ ハッケツビョウ

Search this article

Abstract

<p>A 64-year-old woman was admitted to our hospital to undergo allogeneic stem cell transplantation. She was diagnosed with polycythemia vera with a JAK2 V617F mutation 7 years ago. She was administered ruxolitinib for splenomegaly two years prior to admission but this was discontinued because of progressive pancytopenia. One months after cessation of ruxolitinib, she developed acute myeloid leukemia transformed from post-polycythemia vera myelofibrosis. Although she achieved complete remission after induction therapy, 8-finger-breadth splenomegaly remained below the left costal margin. Ruxolitinib was re-administered following two courses of consolidation therapy. She underwent unrelated peripheral blood stem cell transplantation. Ruxolitinib was administered until the day before transplantation, and the spleen was palpated in 4-finger breadth below costal arc. Neutrophil engraftment was achieved 13 days after transplantation. In allogeneic stem cell transplantation, splenomegaly is one of the risk factors for engraftment failure and/or therapy-related mortality. Hence, a smaller spleen size can theoretically improve the outcome after transplantation. The administration of ruxolitinib prior to transplantation may have contributed to engraftment with a non-invasive reduction in the size of the spleen.</p>

Journal

  • Rinsho Ketsueki

    Rinsho Ketsueki 58 (7), 743-748, 2017

    The Japanese Society of Hematology

Details 詳細情報について

Report a problem

Back to top